tetano
Editor, Senior Moderator
Vaccine. 2015 Jun 19. pii: S0264-410X(15)00696-9. doi: 10.1016/j.vaccine.2015.05.044. [Epub ahead of print]
[h=1]Influenza bivalent vaccine comprising recombinant H3 hemagglutinin (HA) and H1 HA containing replaced H3 hemagglutinin transmembrane domain exhibited improved heterosubtypic protection immunity in mice.[/h] Liu Q[SUP]1[/SUP], Xue C[SUP]2[/SUP], Zheng J[SUP]2[/SUP], Liu K[SUP]2[/SUP], Wang Y[SUP]2[/SUP], Wei Y[SUP]2[/SUP], Liu GD[SUP]3[/SUP], Cao Y[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza caused by infection of influenza viruses is still a leading cause of morbidity and mortality in human. Vaccination is the main defense against influenza virus, but current influenza trivalent or quatrivalent vaccines (TIV/QIV) would lose their effectiveness when vaccine strains are mismatched with circulating strains. Our early study showed that recombinant influenza Hx-TM HA proteins containing H3 HA transmembrane domain(TM) had improved immunogenicity and heterosubtypic protection over corresponding wild-type Hx-WT HA proteins. In present study, bivalent vaccines containing H3-WT+Hx-TM were investigated for their immune responses and heterosubtypic protection immunities. The data showed that the bivalent vaccines containing H3-WT and H5-TM or H1-TM had improved immune responses and heterosubtypic protection over the bivalent vaccines containing H3-WT and H5-WT or H1-WT respectively. These results demonstrated that the improved immune responses and heterosubtypic protection of Hx-TM HA proteins could be translated into bivalent vaccines, suggesting a feasible strategy of improving the immune responses and heterosubtypic protection of influenza multivalent vaccines such as TIV and QIV.
Copyright ? 2015 Elsevier Ltd. All rights reserved.
[h=4]KEYWORDS:[/h] Heterosubtypic protection; Influenza A virus; Multivalent vaccine
PMID: 26100927 [PubMed - as supplied by publisher]
[h=1]Influenza bivalent vaccine comprising recombinant H3 hemagglutinin (HA) and H1 HA containing replaced H3 hemagglutinin transmembrane domain exhibited improved heterosubtypic protection immunity in mice.[/h] Liu Q[SUP]1[/SUP], Xue C[SUP]2[/SUP], Zheng J[SUP]2[/SUP], Liu K[SUP]2[/SUP], Wang Y[SUP]2[/SUP], Wei Y[SUP]2[/SUP], Liu GD[SUP]3[/SUP], Cao Y[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza caused by infection of influenza viruses is still a leading cause of morbidity and mortality in human. Vaccination is the main defense against influenza virus, but current influenza trivalent or quatrivalent vaccines (TIV/QIV) would lose their effectiveness when vaccine strains are mismatched with circulating strains. Our early study showed that recombinant influenza Hx-TM HA proteins containing H3 HA transmembrane domain(TM) had improved immunogenicity and heterosubtypic protection over corresponding wild-type Hx-WT HA proteins. In present study, bivalent vaccines containing H3-WT+Hx-TM were investigated for their immune responses and heterosubtypic protection immunities. The data showed that the bivalent vaccines containing H3-WT and H5-TM or H1-TM had improved immune responses and heterosubtypic protection over the bivalent vaccines containing H3-WT and H5-WT or H1-WT respectively. These results demonstrated that the improved immune responses and heterosubtypic protection of Hx-TM HA proteins could be translated into bivalent vaccines, suggesting a feasible strategy of improving the immune responses and heterosubtypic protection of influenza multivalent vaccines such as TIV and QIV.
Copyright ? 2015 Elsevier Ltd. All rights reserved.
[h=4]KEYWORDS:[/h] Heterosubtypic protection; Influenza A virus; Multivalent vaccine
PMID: 26100927 [PubMed - as supplied by publisher]